Editorial
Pharmacy and Laboratory Collaboration Jacyntha Sterling, PharmD p A lthough they function independently, pharmacy and laboratory services are still entwined. Safe dosing of many medications is correlated to laboratory assessments of renal or hepatic function. In addition to clinical signs and symptoms, the monitoring of drug effect is dependent upon reliable, accurate laboratory assessment. How often do pharmacists take for granted the values that appear on the laboratory report?
In January 2010, the US Food and Drug Administration (FDA) issued a MEDWATCH alert notifying health care professionals of the necessity to communicate with local laboratories regarding the assay method used to measure sirolimus concentrations. As chromatographic and immunoassay technologies are not interchangeable, patient care may be compromised if patients are not consistently monitored with one assay type. Pharmacists should investigate which assay method is employed by their institutions, whether changes in assay type have occurred, and whether the reference ranges for their institution or referring centers have been modified. 1 Sirolimus monitoring is not the only recent change in laboratory parameters. Laboratories have also been adopting a new calibration method to standardize creatinine assays, reducing interlaboratory variation in the reporting of creatinine values. 2 Implications for determining drug doses in patients with diminished renal function should be considered.
In October 2009, the FDA alerted health care professionals to a change in the United States Pharmacopeia (USP) reference standard for heparin that would result in an approximate 10% potency reduction for product marketed in the United States. 3, 4 Little guidance has been provided by the FDA or USP regarding the potential impact on laboratory determination of therapeutic range and dosing nomograms, but helpful considerations have been outlined by the College of American Pathologists. 5 The enzyme rasburicase (Elitek) is now FDAapproved for the initial management of plasma uric acid levels in certain pediatric and adult oncology pa-tients at risk for hyperuricemia secondary to treatmentrelated tumor lysis. A boxed warning for this agent outlines the need to collect blood samples to monitor uric acid in prechilled tubes containing heparin, to immediately immerse and maintain the sample in an ice water bath, and to assay within 4 hours. 6 The American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists published recommendations for vancomycin therapeutic monitoring in 2009. 7 All of the changes in laboratory reporting mentioned above require pharmacist interaction to determine the impact and to direct potential adjustments in dosing or monitoring of the drugs involved. Routine processes that depend on good communication between pharmacy and laboratory services include evaluation of drug-lab interferences, therapeutic drug monitoring, drug dose adjustments due to changing renal or hepatic function, timing of laboratory collections, and turnaround time for reporting laboratory results. As medical care evolves, new opportunities emerge for collaboration between pharmacy and laboratory services.
Trends to adopt computerized physician order entry and electronic medical record systems create opportunities for integration of information that may guide medical decision making. Electronic medical record systems with integrated laboratory data present opportunities to create criteria-based notifications to quickly identify patients who may require dose adjustments or therapy changes. Antimicrobial stewardship programs could benefit from coordination of culture and sensitivity data and antimicrobial order data to help identify candidates for de-escalation or therapeutic modification.
A review of ASHP Best Practice statements and guidelines does not reveal a topic focused on pharmacy and laboratory collaboration. An ASHP Therapeutic Position Statement on adult outpatient acute deep vein thrombosis (DVT) treatment recognizes that collaboration with laboratory personnel, among many other departments and individuals, is important to the success of *Assistant Editor, Hospital Pharmacy; Drug Information Specialist, Saint Francis Hospital, Tulsa, Oklahoma.
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Volume 45, April 2010 such programs. 8 An ASHP statement on clinical pharmacokinetic monitoring calls for collaboration between pharmacists and other drug monitoring process participants. 9 A policy statement from 1992 is posted on the Website for the College of American Pathologists addressing pharmacist scope of practice and laboratory testing responsibility; the statement describes that laboratory test interpretation ''constitutes the practice of medicine, for which pharmacists should not be licensed.'' 10 Pharmacy and laboratory departments sometimes function figuratively behind closed doors and lack awareness of the needs of the other department or the opportunities that collaboration may provide. These departments should lead the way to enhanced collaboration by establishing routine communications. Hospital Pharmacy is interested in what your institutions have developed to foster these communications between laboratory and pharmacy departments.
